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A B S T R A C T
Background: Lofexidine is an alpha-2-adrenergic receptor agonist approved in the United Kingdom (UK) for the
treatment of opioid withdrawal symptoms. Lofexidine has demonstrated better efficacy than placebo for
reducing opioid withdrawal symptoms in patients undergoing opioid withdrawal with less reported hypotension
than clonidine.
Methods: Designed as an FDA registration trial, this 8-day, randomized, double-blind, placebo-controlled,
parallel-group study in 264 patients dependent on short-acting opioids evaluated the efficacy of lofexidine
hydrochloride in reducing withdrawal symptoms in patients undergoing opioid withdrawal. The primary
efficacy measures were SOWS-Gossop on Day 3 and time-to-dropout. Secondary endpoints included the
proportion of participants who were completers; area under the 5-day SOWS-Gossop – time curve (i.e.,
AUC1–5), and daily mean SOWS-Gossop, OOWS‐Handelsman, MCGI (subject and rater), and VAS-E scores.
Participants received lofexidine HCl 3.2 mg daily in four divided doses or matching placebo on Days 1–5,
followed by 2 days of placebo.
Results: Lofexidine significantly decreased mean Day 3 SOWS scores compared to placebo, 6.32 versus 8.67,
respectively, p = 0.0212. Fewer lofexidine patients were early terminators compared to placebo (59 versus 80,
respectively); and non-completers in the lofexidine group remained in the study longer than those assigned to
placebo (p = 0.0034). Secondary endpoints consistently favored lofexidine. Lofexidine was well tolerated in this
trial.
Conclusion: Lofexidine significantly decreased SOWS scores compared to placebo and demonstrated better
retention rates in participants undergoing opioid withdrawal. Lofexidine potentially offers a useful non-opioid
alternative to treat opioid withdrawal symptoms.
1. Introduction
Opioid dependence (Diagnostic and Statistical Manual of Mental
Disorders – Fourth Edition, DSM-IV)/opioid use disorder (OUD; DSM-V)
is epidemic in the United States (US). Heroin-related overdose deaths
between 2002 and 2013 increased by 286%; in 2014 there were 10,574
heroin overdose deaths and 18,893 deaths from prescription opioids
(CDC ADDR_drug_poisoning_involving_OA_heroin_US_2000-2014CDC
ADDR, 2000CDC ADDR_drug_poisoning_involving_OA_heroi-
n_US_2000-2014). To combat this epidemic, increased treatment op-
tions and access to Medication-Assisted Treatment (MAT) for OUD are
essential.
While opioid withdrawal may not be an effective long-term treat-
ment for OUD, withdrawal is often a necessary first step before
naltrexone treatment, for patients who are treated with opioids for
chronic pain who do not have OUD and need to be withdrawn because
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of inefficacy or side effects, and as the final stage after a prolonged
period of agonist therapy.
Methadone and buprenorphine are employed as pharmacological
withdrawal treatments, but their use can be limited by restricted access
(e.g., policy, physician licensing) related to their abuse potential. Use of
alpha-2-adrenergic agonists, primarily clonidine, as an alternative
treatment to aid withdrawal began in the 1980’s (Kleber et al., 1985;
Preston and Bigelow, 1985; Gossop, 1988). Although commonly used in
the US (Gossop, 1988), clonidine is not approved by the Food and Drug
Administration (FDA) for this indication, and its use is limited by
sedation and hypotension at doses effective in alleviating opiate with-
drawal symptoms (Kleber et al., 1985; Preston and Bigelow, 1985).
Lofexidine hydrochloride, also an alpha-2-adrenergic receptor agonist,
is approved for this indication in the United Kingdom (UK) and has
been used in inpatient and outpatient settings since 1992.
Gowing and colleagues have recently reviewed studies assessing
alpha adrenergic agonists for opioid withdrawal (Gowing et al., 2016).
A total of 26 studies involving 1728 participants and meeting pre-
defined quality criteria were included. Six studies compared adrenergic
agonist treatment to placebo but only one assessed lofexidine (Yu et al.,
2008). In that double-blind study, opioid dependent participants were
initially stabilized on morphine, abruptly withdrawn, and then treated
with lofexidine (0.8 mg QID, p.o.) or placebo for 5 days, followed by 2
additional days on placebo. Lofexidine significantly decreased the
scores on The Modified Himmelsbach Opiate Withdrawal Scale
(MHOWS) on study Day 5 (withdrawal Day 2) compared to placebo.
Secondary outcomes favored lofexidine. Lofexidine was associated with
significantly fewer early terminations than placebo. Side effects of
asthenia, dizziness, hypotension, insomnia and somnolence occurred
more frequently with lofexidine compared to placebo.
The remaining five controlled studies compared placebo to cloni-
dine and found less severe withdrawal with clonidine and more
participants dropping out early with placebo (Gerra et al., 1995); fewer
participants with severe withdrawal in the clonidine groups (Batey
et al., 1987; Benos, 1985); and lower withdrawal scores with clonidine
versus placebo (Benos, 1985). Side effects with clonidine included
sedation and dry mouth (Benos, 1985) and drowsiness and dizziness
(Batey et al., 1987). One study reported no difference in side effects
between clonidine and placebo (Nazari et al., 2013). Completion of
withdrawal treatment was reported more likely with clonidine (Batey
et al., 1987; Benos, 1985).
The other studies meeting review qualifications compared alpha-
adrenergic agonists (primarily clonidine and lofexidine) with metha-
done and symptomatic medications and several compared different
alpha-adrenergic agonists. The authors concluded that there was no
significant difference in efficacy of lofexidine and clonidine compared
to methadone reduction (see also Kahn et al., 1997; Carnworth and
Hardman, 1998; Lin et al., 1997); methadone had fewer side effects
than clonidine; and lofexidine had a better safety profile than clonidine
(Gowing et al., 2016). The signs and symptoms of withdrawal occurred
and resolved earlier with alpha-2-adrenergic agonists, and the duration
of treatment was significantly longer with reducing doses of metha-
done. Studies suggest that lofexidine has less hypotensive effects than
clonidine at doses effective for the alleviation of opioid withdrawal and
has no abuse potential (Gowing et al., 2004; Gerra et al., 2001; Strang
et al., 1999).
Lofexidine is under development for approval in the US by US
WorldMeds, LLC. This report describes a Phase 3 efficacy/safety study
designed as a registration study to meet FDA requirements. As
recommended by the FDA, it compared lofexidine to placebo in a
population undergoing abrupt discontinuation from chronically admi-
nistered short-acting opioids.
2. Methods
2.1. Participants
Eligible participants included individuals who were at least 18 years
of age and seeking treatment for opioid dependence (DSM-IV), met
Structured Clinical Interview Axis I (SCID) criteria for dependence on a
short-acting opioid, self-reported opioid use ≥21 of the last 30 days,
showed signs of withdrawal just before randomization (score of ≥2 on
the Handelsman Objective Opiate Withdrawal Scale [OOWS-
Handelsman]), had a urine screen positive for opioids but negative
for methadone or buprenorphine, provided written informed consent
and completed the Addiction Severity Index (ASI) during screening and
all other assessments (Short Opiate Withdrawal Scale [SOWS-Gossop],
OOWS-Handelsman, and Modified Clinical Global Impression [MCGI])
during the baseline period.
Exclusion criteria included any serious medical or psychiatric
illness, self-reported Acquired Immune Deficiency Syndrome, clinically
significant abnormal lab values or dependence on any psychoactive
substance (other than opioids) that required withdrawal; abnormal
cardiovascular exam, including prolonged QTc (> 450 msec for
males,> 470 msec for females); significant hypertension (> 160/
100 mmHg) or hypotension (< 90/60 mmHg); bradycardia
(< 45 bpm); history of myocardial infarction; use of methadone or
buprenorphine in last 14 days; use of psychotropics, prescription
analgesics, anticonvulsants, anti-hypertensives, anti-arrhythmics, anti-
retroviral, or cholesterol lowering agents in last 4 weeks; donation of
blood in last 8 weeks; participation in another investigational study in
last 3 months; inadequate venous access; active tuberculosis or syphilis;
and pregnancy or lactation.
2.2. Procedure and medications
This trial was performed by US WorldMeds, LLC, Louisville, KY, in
collaboration with the National Institute on Drug Abuse (NIDA) and the
Cooperative Studies Program of the Department of Veterans Affairs.
This 15-site study was conducted in the US between June 16, 2006 and
October 26, 2007 in accordance with the provisions of the Declaration
of Helsinki and with the clinical research guidelines embodied in the
International Conference on Harmonization (ICH) Good Clinical
Practice (GCP) guidelines. Monitoring for adherence to GCPs was done
routinely. The protocol and informed consent were reviewed and
approved by each center’s Institutional Review Board and the
Veterans Administration Cooperative Studies Program Coordinating
Center’s Human Rights Committee. All participants reviewed and
signed written informed consent before any study-related procedures
were performed.
Eligible participants were dosed orally with lofexidine HCl 0.8 mg
(4 × 0.2 mg lofexidine HCl tablets) four times daily (QID) for a total
daily dose of 3.2 mg/day, or matching placebo on study Days 1 through
5 followed by placebo (4 tablets) QID on Days 6–7. Drug and placebo
were supplied by US WorldMeds. Lofexidine HCl 0.2 mg tablets contain
0.18 mg lofexidine base (for a total daily dose per protocol of 2.88 mg).
For ethical reasons and practical considerations, specified non-
opioid, symptomatic concomitant medications were allowed when
requested by the participants and approved by the study physician
including multivitamins, guaifenesin, alumina, magnesia, simethicone,
dioctyl sodium sulfosuccinate, psyllium hydrocolloid, bismuth sulfate,
acetaminophen, zolpidem, and nicotine replacement therapy.
2.3. Randomization and blinding
Randomization across all sites employed a centralized Interactive
Touch Tone Randomization System and allocated patients to treatment
groups in a 1:1 ratio. An adaptive randomization procedure was used to
allocate treatment assignment based on the assignments and prognostic
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variable levels for all previously enrolled patients. Randomization used
a “biased coin” procedure, which used randomization probabilities
favoring the treatment with the deficit enrollment (Efron, 1971).
2.4. Design
This was an 8-day inpatient, randomized, multicenter, double-blind,
placebo-controlled, parallel-group study with three phases.
2.4.1. Screening phase (outpatient days −7 to −1)
Participants meeting eligibility criteria were randomized no later
than the morning of the 7th screening day. Participants were admitted
to the inpatient unit on the evening of Day 0 or early in the morning of
Day 1, with baseline assessments completed just before randomization
on Day 1. Screening was completed on an outpatient basis, while
baseline data were collected as inpatients just prior to randomization.
2.4.2. Treatment phase (Days 1–5)
Participants received their first dose of study medication (lofexidine
or placebo) on Day 1 at 08:00 h and were then dosed with 0.8 mg of
lofexidine HCl or matching placebo 4 times daily (QID) for a total daily
dose of 3.2 mg on Days 1–5. Daily dosing windows were scheduled at
08:00 h, 13:00 h, 18:00 h, and 23:00 h.
2.4.3. Post-treatment phase (Days 6–7)
All participants received placebo (four tablets QID) on Days 6 and 7.
On Day 8, no medication was administered and participants were
discharged after completing required assessments.
2.5. Assessments
Co-primary outcome measurements included the SOWS-Gossop
scale (Gossop, 1990) on Day 3 of the treatment phase and time to
study dropout. Day 3 was chosen to be at or near the anticipated peak of
withdrawal as per FDA recommendation. Area-under-the-SOWS-Gos-
sop-time curve (AUC) was the principal secondary outcome measure.
SOWS-Gossop (total score) was chosen because of its sensitivity to
symptom relief during acute opioid withdrawal, validation as an opioid
withdrawal measure (e.g., Bradley et al., 1987; Vernon et al., 2016) and
frequent use in similar drug trials. This subject-rated scale consists of 10
items, scored from 0 (none) to 3 (severe) (total range 0–30). Studies
indicate that a change score of 2–4 points is a clinically meaningful
improvement (e.g., Vernon et al., 2016). The SOWS was completed at
baseline (immediately before first drug administration), 3.5 h after the
first dose of study medication on Days 1–7 and at discharge (Day 8).
Time-to-dropout was chosen as a global assessment of efficacy (i.e.,
treatment retention). Each study day was divided into four 6 h time
quadrants (i.e., 6am–12pm; 12pm–6pm; 6pm–12am; and, 12am–6am)
and time-to-dropout was measured as the number of 6 h time quadrants
until withdrawal or completion of the 5-day Treatment Phase.
Additional assessments included the OOWS (Handelsman et al.,
1987), MCGI (patient and rater forms) and Visual Analog Scale for
Efficacy (VAS-E) assessing the efficacy of study medication for decreas-
ing withdrawal sickness collected at screening, baseline, once daily at
3.5 h following the 0800 medication dose and before discharge. Also
evaluated were: use of concomitant medications to alleviate withdrawal
symptoms; requirement for opioid rescue for symptom relief; and
withdrawal-related adverse events (AEs).
Adverse events (AEs) were assessed daily at approximately the same
time using a non-specific query. Participants could also spontaneously
report AEs any time. All AEs were reviewed with the subject by a study
physician.
12-lead electrocardiograms (ECGs) were conducted during screen-
ing, at clinic admission, 4 h after the first dose of study medication each
day, and before discharge. Vital signs were collected at screening,
baseline, within 30 min before each dose of study medication, 3 h after
the first dose of study medication each day, and before discharge.
Physical exams were performed at screening, baseline, 3–4 h after
randomization on Day 1 and before discharge. Standard clinical
laboratory exams were done at screening, before discharge and as
needed.
2.6. Data analyses
A sample of 264 participants was needed to provide sufficient power
for the analyses of both the primary outcomes. The sample size was
calculated based on assumptions derived from an earlier study of
lofexidine in a similar patient population (Yu et al., 2008). For
SOWS-Gossop on Day 3, a sample size of 264 was estimated, assuming
a minimal clinically significant difference (drug versus placebo) of 5
points, a standard deviation of 10, a power level of 90%, statistical
significance of 0.05, a 1:1 allocation of participants to lofexidine or
placebo, and a 35% attrition rate. For time-to-dropout (the second co-
primary outcome variable), a sample size of 224 was estimated based
on retention rate data from the earlier study.
The Intent-to-Treat population (ITT) includes all randomized pa-
tients. The Evaluable population includes all randomized patients who
received at least one dose of study medication and completed the post-
medications SOWS-Gossop on Day 1 or on any subsequent day.
Completers include all randomized patients who received at least one
dose of study medication on Day 5 and completed the SOWS-Gossop on
Day 5 or on any subsequent day.
SOWS-Gossop score on Day 3 for the Evaluable population used a
prescribed multiple imputation technique to estimate missing data
(Alison, 2001; Rubin, 1987). These scores were compared between
treatment groups using an analysis of covariance (ANCOVA) model
adjusted for baseline SOWS-Gossop scores and using the pre-randomi-
zation opioid dependence severity score (SCID) as a covariate, because
participants with a range of dependence severities were enrolled. For
time to dropout, a log rank test compared the risk-adjusted dropout
rates between treatment groups.
The principal secondary analyses of area-under-the-withdrawal-
symptoms (i.e., SOWS Gossop scores)-time curve (AUC) for the 5-day
Treatment Phase and entire 8‐day study were computed using daily
SOWS-Gossop scores. Kaplan-Meier curves present the proportion of
participants who completed the 5-day Treatment Phase and 8-day study
as the survival probability by treatment group over the entire study
duration.
Other secondary analyses included: Day 3 SOWS-Gossop (ITT and
Completer populations); repeated measures analyses over days (SOWS-
Gossop; OOWS-Handelsman; VAS-E; and MCGI severity); and conco-
mitant medication use. Statistical analyses were done using Analysis of
Covariance (ANCOVA), t-test, Chi-square test, or Fisher’s exact test, as
appropriate. For repeated measures analyses, p < 0.01 was used as a
cut-off for statistical significance; otherwise p < 0.05 was used.
The proportion of participants with each type of AE was compared
between treatment groups using Fisher’s exact test. Electrocardiogram
variables were analyzed using an ANCOVA model adjusted for baseline
readings. Mean changes from baseline in vital signs data were analyzed
using t-tests. A paired t-test was used to compare baseline to end of
study clinical laboratory values and an unpaired t-test compared
treatment groups with respect to change from baseline.
A Data and Safety Monitoring Board reviewed the study annually.
3. Results
3.1. Participant disposition and demographics
Four hundred forty-eight participants were screened for eligibility
of which 264 were enrolled and randomized to treatment (134 on
lofexidine and 130 on placebo, for a screen fail rate of 40.8%; Fig. 1).
Eighty-five participants completed the trial (50/134 [37.3%] lofexidine
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participants and 35/130 [26.9%] placebo participants) for an overall
retention rate of 32.2%. Specific reasons for subject discontinuation are
provided in Fig. 1.
No significant differences were found between treatment groups on
any demographic parameter. The mean (Standard Deviation, SD) age of
study participants was 36.8 ± 10.9 years; the majority were male
(75.8%) (Table 1).
All participants met DSM-IV Revised criteria for opioid dependence.
The primary opioid of abuse for the lofexidine and placebo groups,
respectively, were: heroin (63.8%, 61.2%); oxycodone (19.4%, 23.1%);
and hydrocodone (17.2%; 11.5%). Approximately 71% and 75% of
patients in the lofexidine and placebo groups, respectively, were taking
other medications before study start (most commonly analgesics, sleep
aids, and benzodiazepines).
As per FDA recommendation, this was an “all comers” study; all
participants meeting admission criteria were eligible, regardless of their
particular opioid of choice, amount or duration of use. At randomiza-
tion all participants were in early withdrawal (with OOWS score of at
least 2). The large N was chosen to account for expected variability.
3.2. Co-primary outcome measures
Statistical significance was achieved for both co-primary endpoints
(SOWS-Gossop and time-to-dropout) favoring lofexidine.
3.2.1. SOWS-Gossop on day 3 (3rd day of medically supervised opioid
withdrawal)
The mean Day 3 SOWS-Gossop score was approximately 2.4 points
lower in the lofexidine group than the placebo group, (p = 0.0212)
(Table 2). The peak difference in mean SOWS-Gossop scores between
treatment groups occurred on Day 2 and placebo scores remained
higher than lofexidine scores throughout the 5-day Treatment Phase
(Fig. 2). Upon treatment discontinuation, some rebound in lofexidine
group scores occurred indicating a mild withdrawal syndrome persisted
beyond five days.
3.2.2. Time-to-dropout
Fewer participants in the lofexidine group were early terminators
compared to the placebo group, and non-completers in the lofexidine
group remained in the study longer than those assigned to placebo
(p = 0.0034; Table 3).
3.3. Principal secondary outcome analyses
3.3.1. AUC
Over the 5-day Treatment Phase, AUCs were lower in the lofexidine
Fig. 1. Flow diagram for the randomized controlled trial of lofexidine.
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group than the placebo group for the ITT and Completer populations
(p = 0.0260 and p = 0.0188, respectively) (Table 4). Over the entire 8-
day study, AUCs were also significantly lower in the lofexidine versus
placebo group for the Completer population (p = 0.0306) and showed
a trend for the ITT population (p = 0.0979).
3.3.2. Proportion of completers
Lofexidine-treated participants stayed in the trial longer than
placebo-treated participants for the 5-day Treatment Phase and entire
8 days (Fig. 3). Likewise, a greater proportion of lofexidine-treated
participants completed withdrawal than placebo-treated participants,
which was statistically significant for those meeting the Completer
definition (p = 0.0030) and those completing the entire 5-day Treat-
ment Phase (p = 0.0087), with a trend for completion of the entire
8 days (p = 0.0867) (Table 5).
3.4. Other secondary analyses
Lofexidine consistently demonstrated a positive effect versus place-
bo on relief of opioid withdrawal over a variety of measures. Of the
listed analyses of opioid withdrawal symptoms in Table 6, 11 of the 14
analyses showed either a statistically significant difference or a trend
favoring lofexidine over placebo. The average number of withdrawal-
related AEs was less in the lofexidine group than the placebo group for
the 5-days of active treatment, but greater than placebo when
lofexidine was discontinued (Days 6, 7 and 8). During the study, only
two participants in the lofexidine group and three participants in the
placebo group were given opioid rescue medications.
3.5. Safety monitoring variables
3.5.1. Blood pressure and heart rate
No differences in pre-dose sitting blood pressure or heart rate were
apparent between the treatment groups at baseline. On initiation of
lofexidine, blood pressure dropped and remained relatively constant
throughout the 5-day Treatment Phase (Fig. 4). Mean systolic pressure
dropped about 15 mmHg and diastolic pressure dropped approximately
9 mmHg in lofexidine-treated participants, with a statistically signifi-
cant difference (p < 0.01) between the treatment groups on Days 1–6,
but not on Day 7. The same pattern of blood pressure changes was seen
for the other three measurement conditions (predose standing and 3 h
post initial daily dose both sitting and standing). Orthostatic measure-
ments showed about a 50% greater decrease with lofexidine compared
to sitting values. Likewise, the 3 h post-dose measurements showed
slightly greater drops than the pre-dose measurements.
Mean sitting heart rate was lower following lofexidine administra-
tion over the first 3 days of treatment, then gradually increased above
baseline value after lofexidine discontinuation on Day 6, (Fig. 4). In the
placebo group, heart rate steadily increased over the course of the
study. The difference between treatment groups was statistically
significant for Days 1–5 (p < 0.0001 for all 5 days). The same general
pattern of heart rate changes was seen in the other three treatment
assessments; however, in standing conditions, a reflex tachycardia
mitigated some of the bradycardic effects of lofexidine and the
magnitude of pulse decreases were less compared to sitting conditions.
In general, all mean changes were less than 10 bpm versus baseline
with the maximum mean change of 14 bpm (baseline versus Day 7)
seen in the placebo group in the 3 h post-dose standing condition.
Although adverse events were not directly linked to vital sign
assessments, 22.4% of lofexidine participants reported dizziness (versus
6.9% on placebo), many of which were likely caused by hypotension or
orthostatic hypotension. One subject on the fifth day of lofexidine
treatment had a syncopal episode, which resolved quickly with no
treatment or sequelae.
3.5.2. QTc prolongation
The study was not designed for robust assessment of cardiac
repolarization effects. However, on daily ECGs, obtained at approxi-
mately peak lofexidine concentration, no meaningful difference was
found in mean QTc values (using the Bazett correction) between the
treatment groups for any population (ITT, Evaluable, and Completer)
evaluated. Means varied between approximately 402 and 410 msec.
There was no clinically meaningful difference in change from baseline
between treatment groups on any day. Mean QTc values decreased over
the course of the study for both groups except for a mean increase from
baseline of 0.7 msec on Day 1 in the lofexidine group.
Six participants (two on lofexidine, four on placebo) had prolonged
QTc intervals reported as AEs. Of the lofexidine-treated participants,
one was discontinued from the trial because QTc interval readings on
day 1 (471- 483 msec) exceeded the protocol-specified cut-off. The
other lofexidine-treated subject had prolonged QTc interval on Days 2,
3, and 4, but this observation was subsequently found to be likely due
to an error in the machine reading. In those participants with QTc
prolongation, the QTc interval rapidly returned to within normal limits
and in no case did the PI or consultant feel that additional cardiovas-
cular studies were necessary.
3.5.3. Adverse events
Overall, 130 participants (97.0%) in the lofexidine group and 122
Table 1
Baseline demographics.
Demographic Lofexidine
(N = 134)
Placebo
(N = 130)
Total
(N = 264)
p-Value
Age (in years)
Mean ± S.D. 36.1 ± 11.2 37.6 ± 10.7 36.8 ± 10.9 0.2749a
Race (N, %)
White 63 (47.0) 76 (58.5) 139 (52.7) 0.1796b
Black 37 (27.6) 27 (20.8) 64 (24.2)
Hispanic 34 (25.4) 27 (20.8) 61 (23.1)
Total 134 (100.0) 130 (100.0) 264 (100.0)
Gender (N, %)
Male 101 (75.4) 99 (76.2) 200 (75.8) 0.8870b
Female 33 (24.6) 31 (23.8) 64 (24.2)
Total 134 (100.0) 130 (100.0) 264 (100.0)
Education (in years)
Mean ± S.D. 12.0 ± 1.9 12.1 ± 1.9 12.1 ± 1.9 0.6917a
Employment past 3 years (N, %)
Employed 97 (72.4) 88 (67.7) 185 (70.1) 0.7731b
Student 1 (0.7) 2 (1.5) 3 (1.1)
Retired/Disability 5 (3.7) 5 (3.8) 10 (3.8)
Unemployed 31 (23.1) 35 (26.9) 66 (25.0)
Total 134 (100.0) 130 (100.0) 264 (100.0)
Marital Status (N, %)
Ever Married 70 (52.2) 72 (55.4) 142 (53.8) 0.6234b
Never Married 64 (47.8) 58 (44.6) 122 (46.2)
Total 134 (100.0) 130 (100.0) 264 (100.0)
a t-Test.
b Chi-Square.
Table 2
SOWS-Gossop scores (Evaluable Population analyses).
Lofexidine Placebo
Analysis/Time Point n Mean ± S.D. n Mean ± S.D. p-Valuea
Multiple Imputation
Analysis
Day 3 133 6.32 ± 4.71 126 8.67 ± 5.54 0.0212
a Based on analysis of covariance model adjusted for baseline SOWS-Gossop scores and
using the pre-randomization opioid dependence severity based on SCID (Structured
Clinical Interview for DSM-IV-TR Axis I Disorders) as a covariate.
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participants (93.8%) in the placebo group reported AEs (p = 0.2496)
All reported AEs, regardless of attribution, occurring in at least 5% of
participants are shown in Table 7. AEs considered withdrawal-related
were reported for 85.1% and 87.7% of patients in the lofexidine and
placebo groups, respectively (p = 0.5928). AEs occurring at a signifi-
cantly (p < 0.01) higher rate in the lofexidine group compared to the
placebo group were hypotension, dizziness, dry mouth, and bradycar-
dia, whereas vomiting and lacrimation were significantly (p < 0.01)
higher in the placebo group. Other notable differences include pain in
extremity, sedation, stomach discomfort, malaise, and sinus bradycar-
dia in the lofexidine group and rhinorrhea, feeling hot and cold, and
hypertension in the placebo group. The majority of AEs were classified
as mild to moderate in severity with no significant differences between
treatment groups. AEs of severe intensity occurred in 23.1% and 29.2%
of patients in the lofexidine and placebo groups, respectively.
Sixteen participants (8 on lofexidine, 8 on placebo) experienced AEs
classified as serious (SAEs). Of these 16 SAEs, 9 (4 lofexidine, 5
placebo) were due to severe opioid withdrawal and required study
discontinuation. These 9 required prolonged hospitalization beyond
their discontinuation to achieve stabilization (typically not more than
1 day) and thus met FDA’s SAE definition. The remaining 4 lofexidine
SAEs were for hypotension and/or bradycardia, requiring additional
inpatient monitoring. All 4 participants were discharged after not more
than 1 day of continued assessment. The other 3 SAEs on placebo were
persistent hypertension, second degree heart block and prolonged QTc
(471 msec in a female subject). All of the SAEs reported during the
study resolved rapidly and were without sequelae.
4. Discussion
The present study demonstrates significant efficacy of lofexidine
versus placebo for alleviation of symptoms of opioid withdrawal and
confirms and extends the finding of Yu et al. (2008). The current study
was performed in a similar patient population with differences in study
design and primary outcomes to meet the requests of the FDA. The
morphine lead-in was eliminated and lofexidine was abruptly discon-
tinued after 5 days of administration (0.8 mg QID) with continued
Fig. 2. Effects of lofexidine versus placebo on SOWS-Gossop scores (ITT population).
Table 3
Number of early terminators during the 5‐day treatment phase (Evaluable Population
analyses).
Variable Lofexidine Placebo Log-Rank p-
Value
Number of early terminatorsa 59 80
Mean time quadrants to early
terminationb
6.9 6.4 0.0034
a Defined as any subject who withdrew before taking at least one dose of study
medication on Day 5 and before completing the Day 5 or any subsequent day’s SOWS-
Gossop assessment.
b Number of 6 h time quadrants until early termination.
Table 4
Area under the withdrawal symptoms-time curves (AUC).
Analysis Population
Time Point
Lofexidine Placebo
n Mean ± S.D. n Mean ± S.D. p-Valuea
ITT population
5-day active treatment
period
114 20.84 (15.13) 99 25.75 (16.80) 0.0260
8-day study period 114 26.04 (21.28) 99 29.63 (20.64) 0.0979
Completer population
5-day active treatment
period
71 23.97 (16.20) 45 31.86 (17.85) 0.0188
8-day study period 71 32.32 (23.33) 45 40.38 (22.19) 0.0306
a Wilcoxon test.
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blinded dosing of placebo for 2 days to assess the degree, if any, of
rebound effects. Opioid dependence was determined by history,
positive urine toxicology and a minimal score on the OOWS
(Handelsman et al., 1987) of at least 2 just prior to randomization.
Use of the SOWS-Gossop (Gossop, 1990), a subjective scale completed
by participants on Day 3 of withdrawal, better reflected the subjective
withdrawal experience based on symptom severity compared to an
observer rating (MHOWS in the Yu study). Time-to-dropout was
introduced as a co-primary outcome variable.
Despite these differences in study design, there was consistency
between the results of MHOWS and SOWS, as well as results for
retention and the other secondary outcome measures. Differences in the
co‐primary outcome measures reached statistical significance
(p = 0.0212 and p = 0.0034) favoring lofexidine over placebo for both
Day 3 SOWS Gossop score and time-to-dropout, respectively. Sensitivity
analyses confirmed the SOWS-Gossop observations. SOWS scores
peaked on Day 2 of withdrawal but remained lower in the lofexidine
group throughout the 5 days of treatment as demonstrated in the area-
under-the-SOWS versus days curve. Fewer patients in the lofexidine
group were early terminators, and early terminators stayed longer if
they were taking lofexidine (p = 0.0034). Consistent with this finding,
the proportion of patients who completed the 5-day active treatment
period was greater for the lofexidine group than the placebo group
(p = 0.0087). Results from the current study are also in agreement with
other trials of lofexidine (see Introduction), demonstrating that lofex-
idine effectively reduced withdrawal symptoms compared to placebo
Fig. 3. Effects of lofexidine versus placebo on subject retention rate.
Table 5
Proportion of participants completing the study (ITT population).
Variable Lofexidine
(N = 134)
n (%)
Placebo
(N = 130)
n (%)
p-Valuea
Participants completing per protocolb 71 (53.0) 45 (34.6) 0.0030
Participants completing 5-day treatmentc 66 (49.3) 43 (33.1) 0.0087
Participants completing 8-day study periodd 50 (37.3) 35 (26.9) 0.0867
a Fisher’s exact test.
b Received the last dose of study medication on Day 5 and completed the SOWS-Gossop
on Day 5.
c Completed the 5‐day treatment phase and discharged in the first time quadrant of
Day 6 or later.
d Completed the 8‐day study period and discharged in the morning of Day 8.
Table 6
Secondary Efficacy Analyses.
Analysis Analysis
Population
P value, lofexidine versus
placebo
SOWS-Gossop, Day 3 ITT p = 0.0482
SOWS-Gossop, Day 3 Completer p = 0.1045
SOWS, Repeated Measures ITT p = 0.0058
SOWS, Repeated Measures Completer p < 0.0001
OOWS, Repeated Measures ITT p < 0.0001
OOWS, Repeated Measures Completer p < 0.0001
VAS-E, Repeated Measures ITT p = 0.0016
VAS-E, Repeated Measures Completer p = 0.0118
MCGI Severity, Subjects, Repeated
Measures
ITT p = 0.0119
MCGI Severity, Subjects, Repeated
Measures
Completer p = 0.2777
MCGI Severity, Rater, Repeated
Measures
ITT p = 0.1123
MCGI Severity, Rater, Repeated
Measures
Completer p = 0.2444
Concomitant Meds Given (All), No.
Subjects
ITT p = 0.0855
Concomitant Meds Given (All),
Daily Meds Used
ITT p = 0.0003-0.0007 for days
1,2 and 3
p = 0.0730 for day 4
p = 0.0221 for day 5
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and was generally well tolerated.
Safety outcomes were generally favorable, and, consistent with the
findings of the Yu study, lofexidine was well tolerated in this trial. Due,
in part, to opioid withdrawal symptoms, AEs were reported for the
majority of study participants with withdrawal-related AEs reported for
85.1% of lofexidine-treated participants and 87.7% of placebo-treated
participants (p = 0.5928).
Those AEs significantly higher (p < 0.01) in the lofexidine group
versus the placebo group included hypotension, dizziness, dry mouth,
and bradycardia. Based on lofexidine mechanism of action, a reduction
Fig. 4. Effects of lofexidine on systolic (top graph) and diastolic (middle graph) average predose sitting blood pressure and heart rate (bottom graph).
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in blood pressure was expected. On initiation of lofexidine, mean
systolic and diastolic pressure dropped ∼15 mmHg and 9 mmHg,
respectively, remaining relatively stable throughout the treatment
phase. Most instances of hypotension were non-symptomatic and did
not require intervention. On abrupt lofexidine discontinuation, blood
pressure rose slightly above placebo levels, but there was no clinically
significant rebound hypertension.
The safety profile observed for lofexidine in this study was
consistent with other lofexidine clinical studies for treatment of opioid
withdrawal. In the systematic review by Gowing et al. (2016),
hypotensive or other adverse effects were more likely with alpha-2-
adrenergic agonists, but this did not translate into a significant
difference in withdrawal treatment completion rates. Despite the
occurrence of hypotension in the current study, completion rates
remained higher for those on lofexidine than placebo. Available data
suggest that lofexidine has a better safety profile with a smaller
reduction in blood pressure than clonidine (Gowing et al., 2016);
however, a comparative study has not been performed with the dose of
lofexidine administered in the current trial.
In the present study, lofexidine significantly alleviated symptoms of
opioid withdrawal, resulted in longer patient retention in treatment, a
higher rate of completing the active treatment period, and demon-
strated a favorable safety profile, providing evidence of the potential
benefits of lofexidine as a non-opioid treatment for this indication.
Although the 3.2 mg/day dose has been identified as the maximum
effective dose, future studies may be warranted at a dose of 2.4 mg/day
(consistent with the registered dose in the U.K.) and for longer
durations consistent with 7–14 day withdrawal schedules to further
assess the lofexidine benefit risk profile.
Few medications are approved by the FDA for treating opioid
withdrawal, and there are no current, approved non-opioid treatments
for this use. There is no current evidence that lofexidine has abuse
potential or addictive properties; and thus, it may represent a mean-
ingful advantage over currently employed opioid agonist medications.
Lofexidine potentially offers a safe alternative when a non-opioid agent
or augmentation of an opioid agent is desired or in areas where
methadone or buprenorphine assisted withdrawal are unavailable
(Rosenblatt et al., 2015; Lembke and Chen, 2016).
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Table 7
Number of participants experiencing any adverse event during the 8-day study period
with ≥5% occurrence in total and/or lofexidine-treated participantsa.
Adverse event
MedDRA term
Lofexidine
(N = 134)b
Placebo
(N = 130)b
Total
(N = 264)b
Fisher’s p-
Value
Insomnia 59 (44.0) 55 (42.3) 114 (43.2) 0.80
Headache 47 (35.1) 45 (34.6) 92 (34.8) 1.00
Diarrhea 36 (26.9) 45 (34.6) 81 (30.7) 0.18
Anxiety 35 (26.1) 30 (23.1) 65 (24.6) 0.57
Nausea 35 (26.1) 42 (32.3) 77 (29.2) 0.28
Hypotension 34 (25.4) 1 (0.8) 35 (13.3) < 0.01
Dizziness 30 (22.4) 9 (6.9) 39 (14.8) < 0.01
Dry mouth 19 (14.2) 2 (1.5) 21 (8.0) < 0.01
Restlessness 18 (13.4) 19 (14.6) 37 (14.0) 0.86
Pain 17 (12.7) 25 (19.2) 42 (15.9) 0.18
Abdominal pain
upper
16 (11.9) 20 (15.4) 36 (13.6) 0.47
Chills 16 (11.9) 22 (16.9) 38 (14.4) 0.29
Dyspepsia 15 (11.2) 15 (11.5) 30 (11.4) 1.00
Hyperhydrosis 15 (11.2) 19 (14.6) 34 (12.9) 0.46
Muscle spasms 15 (11.2) 16 (12.3) 31 (11.7) 0.85
Back pain 14 (10.4) 18 (13.8) 32 (12.1) 0.45
Fatigue 14 (10.4) 11 (8.5) 25 (9.5) 0.68
Bradycardia 13 (9.7) 2 (1.5) 15 (5.7) < 0.01
Myalgia 13 (9.7) 21 (16.2) 34 (12.9) 0.14
Somnolence 13 (9.7) 6(4.6) 19 (7.2) 0.15
Constipation 12 (9.0) 5 (3.8) 17 (6.4) 0.13
Pain in extremity 12 (9.0) 2 (1.5) 14 (5.3) 0.011
Rhinorrhea 12 (9.0) 22 (16.9) 34 (12.9) 0.07
Abdominal pain 11 (8.2) 15 (11.5) 17 (9.8) 0.41
Sedation 11(8.2) 2 (1.5) 13 (4.9) 0.02
Yawning 10 (7.5) 14 (10.8) 24 (9.1) 0.40
Tremor 9 (6.7) 15 (11.5) 24 (9.1) 0.20
Muscle twitching 8 (6.0) 9 (6.9) 17 (6.4) 0.81
Musculoskeletal
stiffness
8 (6.0) 5 (3.8) 13 (4.9) 0.57
Nasal congestion 8 (6.0) 6 (4.6) 14 (5.3) 0.79
Depression 7 (5.2) 6 (4.6) 13 (4.9) 1.00
Lacrimation
increased
7 (5.2) 20 (15.4) 27 (10.2) < 0.01
Muscle tightness 7 (5.2) 3 (2.3) 10 (3.8) 0.33
Stomach discomfort 7 (5.2) 1 (0.8) 8 (3.0) 0.07
Vomiting 7 (5.2) 27 (20.8) 34 (12.9) < 0.01
Feeling hot and cold 5 (3.7) 15 (11.5) 20 (7.6) 0.02
a In order of decreasing occurrence in the lofexidine group.
b N (%) of participants.
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